Mednet Logo
CommunityMedical Oncology

What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?

Community PollStarted

What duration ADT do you recommend with salvage pelvic radiotherapy for PSMA PET identified pelvic node relapse after prostatectomy (life expectancy >5 years)?

646 physicians have voted

Join Mednetto vote and see how they answered.

8 Answers
Mednet Member
Mednet Member
Radiation Oncology · The Oregon Clinic-Radiation Oncology West
Answered on

6 months ADT, 2 years ADT, 2 years ADT + abiraterone/prednisone seems reasonable depending on the circumstances. For example, early pelvic node recurrence for pT3b Gleason 4+5 would be a higher risk than a very late recurrence of pT2 Gleason 3+3.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan Kettering Cancer Center
Answered on

Agree that there is some nuance in patient and tumor features, but ultimately this is cancer that has shown it can spread at least to lymph nodes so I generally aim for 2 years and at least discuss Abiraterone. If toxicity is high then can consider cutting short

Things that push me to shorter course...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · SUNY Upstate Medical University
Answered on

While data is lacking in this situation, our default is 2 years of dual ADT.

Our rationale is that dual ADT was of benefit in STAMPEDE for gross nodes (granted not detected by PSMA), and ~2 years is standard for poor-risk localized disease, due in large part to the risk of eventual spread in that po...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Florida
Answered on

At least 6 months, preferably 18 depending on tolerance

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Marshfield Clinic - Rice Lake
Answered on

I use the gleason score of the resected cancer to determine the length of hormonal therapy. If we base our duration of hormonal ablation on the gleason score for primary treatment, why wouldn't we do the same for a nodal "recurrence", which is really untreated primary disease that was present at the...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Texas at Tyler
Answered on

One option may be to assess the androgen sensitivity of the recurrence by using Decipher, provided the area is amenable to biopsy. The result would offer the potential to tailor ADT to the patient.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Hôtel Dieu de Lévis - CISSS Chaudière-Appalaches
Answered on

To answer Dr.@Dr. First Last's question, the Enzalutamide trend might be due to an extrapolation from the EMBARK trial for high-risk biochemical recurrence. Many argue that a PEACE-V approach with 6 months ADT and Enzalutamide (or another ARPI) intensification might be the path forward for PET-PSMA ...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Lafayette Radiation Center
Answered on

Depends on the scenario, the variations above are pretty standard. STORM and Oligopelvis use 6 m ADT monotherapy with RT. That's my minimum. Titrate up from there based on the scenario with max as 2 years ADT and abi. Many guys received salvage RT and maybe ADT and remember being castrated. They won...

Join for free or sign in to see the full answer